Virios Therapeutics, Inc.
http://www.innovativemedconcepts.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Virios Therapeutics, Inc.
Tonix Zeroes In On Fatigue As Go-Forward Endpoint In Long COVID
The company’s Phase II POC trial did not meet the pain primary endpoint, but fatigue may be more relevant in long COVID despite the condition’s overlap with fibromyalgia.
Virios Fibromyalgia Drug Fails Phase IIb And Firm Says COVID-19 May Be To Blame
A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.
Tech Transfer Roundup: How Can Translational Research Help With The Next Pandemic?
Seven international translational research bodies recommend five actions to help better prepare for future outbreaks. Plus an overview of recent COVID-19-focused collaborations.
Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- IMC, Innovative Med Concepts, LLC., Virios Therapeutics, LLC.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice